Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedJul 14, 2026
DataAggregated Company Financials
Companies182
  • 7D0.1%
  • 3M18.0%
  • 1Y12.2%
  • YTD16.5%

Over the last 7 days, the Pharma industry has remained flat, although notably Dr. Reddy's Laboratories declined by 8.0%. The past year has been better, since the industry has gained 12% in that time. As for the next few years, earnings are expected to grow by 16% per annum.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Wed, 15 Jul 2026₹23.8t₹4.5t₹643.1b30x37x5.3x
Fri, 12 Jun 2026₹22.2t₹4.5t₹643.1b28.4x34.5x4.9x
Sun, 10 May 2026₹21.9t₹4.4t₹630.3b29.3x34.7x5x
Tue, 07 Apr 2026₹19.7t₹4.3t₹621.1b26.3x31.7x4.5x
Thu, 05 Mar 2026₹20.2t₹4.3t₹621.2b25.7x32.5x4.6x
Sat, 31 Jan 2026₹19.5t₹4.2t₹604.9b28.6x32.3x4.6x
Mon, 29 Dec 2025₹20.4t₹4.2t₹614.5b28.6x33.2x4.8x
Wed, 26 Nov 2025₹20.3t₹4.2t₹611.6b29.8x33.3x4.8x
Fri, 24 Oct 2025₹20.5t₹4.1t₹590.3b30x34.7x5x
Sun, 21 Sep 2025₹20.7t₹4.1t₹587.9b32x35.3x5.1x
Tue, 19 Aug 2025₹20.4t₹4.1t₹589.0b30.4x34.6x5x
Thu, 17 Jul 2025₹21.0t₹4.0t₹594.1b33.2x35.3x5.3x
Sat, 14 Jun 2025₹20.4t₹4.0t₹595.3b33.7x34.3x5.1x
Mon, 12 May 2025₹19.1t₹3.9t₹565.9b29x33.8x4.9x
Wed, 09 Apr 2025₹18.7t₹3.9t₹559.2b27.9x33.4x4.8x
Fri, 07 Mar 2025₹18.7t₹3.9t₹559.4b27.6x33.5x4.8x
Sun, 02 Feb 2025₹19.7t₹3.9t₹543.8b31x36.2x5.1x
Tue, 31 Dec 2024₹21.2t₹3.8t₹527.0b34.9x40.3x5.6x
Thu, 28 Nov 2024₹20.3t₹3.8t₹526.7b33.7x38.5x5.3x
Sat, 26 Oct 2024₹20.7t₹3.7t₹494.5b37x41.9x5.5x
Mon, 23 Sep 2024₹21.4t₹3.7t₹492.6b41.1x43.4x5.7x
Wed, 21 Aug 2024₹20.5t₹3.7t₹492.6b37x41.6x5.5x
Fri, 19 Jul 2024₹18.8t₹3.6t₹449.9b35x41.7x5.2x
Sun, 16 Jun 2024₹17.7t₹3.6t₹448.3b33x39.4x5x
Tue, 14 May 2024₹16.9t₹3.5t₹428.8b33.8x39.4x4.8x
Thu, 11 Apr 2024₹17.1t₹3.5t₹418.9b33.5x40.9x4.9x
Sat, 09 Mar 2024₹17.1t₹3.5t₹418.7b33.4x40.8x4.9x
Mon, 05 Feb 2024₹16.1t₹3.4t₹408.2b35x39.5x4.7x
Wed, 03 Jan 2024₹15.4t₹3.4t₹395.9b34.3x38.9x4.5x
Fri, 01 Dec 2023₹14.3t₹3.4t₹395.1b31.6x36.1x4.2x
Sun, 29 Oct 2023₹12.8t₹3.3t₹375.3b28.8x34.2x3.9x
Tue, 26 Sep 2023₹12.9t₹3.3t₹369.5b29.8x34.9x3.9x
Thu, 24 Aug 2023₹13.0t₹3.3t₹367.1b29.5x35.5x4x
Sat, 22 Jul 2023₹12.2t₹3.2t₹342.2b26.5x35.7x3.9x
Price to Earnings Ratio

35.7x


Total Market Cap: ₹12.2tTotal Earnings: ₹342.2bTotal Revenue: ₹3.2tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.6x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.6x.
  • The industry is trading close to its 3-year average PS ratio of 4.9x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 23% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Trends

Which industries have driven the changes within the Indian Healthcare industry?

IN Market-0.059%
Healthcare0.088%
Pharma0.14%
Pharma0.14%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.94k2.1%
+₹94.1b		12.5%PE40.6x
LAURUSLABS Laurus Labs₹1.56k5.6%
+₹45.0b		88.7%PE94.8x
500420 Torrent Pharmaceuticals₹4.97k2.4%
+₹39.6b		44.5%PE77.8x
RUBICON Rubicon Research₹1.49k8.1%
+₹18.4b		n/aPE99.6x
500488 Abbott India₹27.52k3.0%
+₹17.2b		-19.8%PE37.7x

Latest News

ZYDUSLIFE
₹1,133.60
Zydus Lifesciences
7D
-1.7%
1Y
17.1%
IPCALAB
₹1,840.40
Ipca Laboratories
7D
2.6%
1Y
25.1%
LAURUSLABS
₹1,560.70
Laurus Labs
7D
5.6%
1Y
88.7%
SUNPHARMA
₹1,942.60
Sun Pharmaceutical Industries
7D
2.1%
1Y
12.5%
500257
₹2,469.45
Lupin
7D
-0.8%
1Y
26.6%
GLAND
₹2,488.30
Gland Pharma
7D
-2.4%
1Y
31.3%
Narrative Update • Jul 08

GLAND: US Injectable Approvals And Dividend Will Support Future Rerating

Analysts have raised the Gland Pharma price target from ₹2,645 to ₹2,835, citing updated assumptions around revenue growth, profit margins and future P/E, which they state support a higher fair value estimate. What’s in the News for Gland Pharma Board meeting on May 15, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, to recommend a final dividend for FY 2025-26, and to approve the grant of 690,019 employee stock options to 124 employees under the Gland Pharma Employee Stock Options Scheme, 2025.
AJANTPHARM
₹3,408.80
Ajanta Pharma
7D
2.8%
1Y
26.4%
Narrative Update • Jul 08

AJANTPHARM: Fair Outlook Will Rely On Upcoming Board Decisions And Auditor Reappointments

Ajanta Pharma's analyst fair value estimate has been revised from ₹3,207.58 to ₹3,342.57 as analysts factor in updated assumptions on the discount rate, revenue growth, profit margin, and future P/E expectations. What's in the News for Ajanta Pharma Ajanta Pharma has scheduled a Board Meeting on May 5, 2026 to consider the audited financial results for the quarter and year ended March 31, 2026.
AUROPHARMA
₹1,552.80
Aurobindo Pharma
7D
-1.9%
1Y
34.8%
Narrative Update • Jul 07

AUROPHARMA: Margin Reset Buyback And New Approvals Will Shape Future Balance

Analysts have raised their price target fair value for Aurobindo Pharma from ₹1,379.96 to ₹1,519.97, citing updated assumptions that now factor in a shift from previously declining revenues to projected revenue growth, a lower profit margin profile, and a slightly higher future P/E multiple. Analyst Commentary Recent research commentary around Aurobindo Pharma gives investors a mixed but useful read on how the updated fair value ties back to expectations for execution, profitability, and growth assumptions.
AETHER
₹1,439.90
Aether Industries
7D
8.3%
1Y
74.7%
New Narrative • Jul 06

Rising CRAMs Pipeline And New Sites Will Reshape Long Term Earnings Power

Catalysts About Aether Industries Aether Industries is a specialty chemicals company focused on custom R&D, contract manufacturing and large scale production across pharma, agrochemicals, material science and oil and gas. What are the underlying business or industry changes driving this perspective?
500124
₹1,245.75
Dr. Reddy's Laboratories
7D
-8.0%
1Y
-1.2%
RUBICON
₹1,491.30
Rubicon Research
7D
8.1%
1Y
n/a
CIPLA
₹1,438.10
Cipla
7D
-0.9%
1Y
-3.5%
500420
₹4,971.25
Torrent Pharmaceuticals
7D
2.4%
1Y
44.5%
Narrative Update • Jun 25

500420: Dividend Payouts And Stable Assumptions Will Support A Balanced Outlook

Analysts have kept their fair value estimate for Torrent Pharmaceuticals steady at about ₹4,878.79 per share, citing unchanged assumptions for revenue growth, profit margins, discount rate, and future P/E multiple. What's in the News for Torrent Pharmaceuticals At its AGM on 23 June 2026, Torrent Pharmaceuticals declared a final dividend of ₹9.00 per equity share of face value ₹5.00 for the financial year ended 31 March 2026.
ALKEM
₹5,601.50
Alkem Laboratories
7D
-1.2%
1Y
13.5%
Narrative Update • Jun 24

ALKEM: Elevated P/E Will Persist Despite New Diabetes And Nutrition Launches

Analysts have trimmed their price target for Alkem Laboratories from ₹4,721.52 to ₹4,557.94, reflecting updated views on revenue growth, profit margins and future P/E assumptions. What's in the News Alkem Laboratories became the first company in India to launch semaglutide in single shot pre filled syringes, with multiple dose strengths starting at ₹350, after receiving approval from the Drugs Controller General of India for Type 2 diabetes and obesity management.
EMCURE
₹1,810.10
Emcure Pharmaceuticals
7D
-1.8%
1Y
32.9%
Narrative Update • Jun 23

EMCURE: Capacity Expansion And Governance Resolutions Will Shape Balanced Forward Outlook

Analysts have nudged their fair value estimate for Emcure Pharmaceuticals from ₹1,891.83 to ₹1,913.50, reflecting updated assumptions around slightly higher revenue growth, a marginally adjusted profit margin, and a modestly higher future P/E multiple. What’s in the News for Emcure Pharmaceuticals Emcure Pharmaceuticals plans to increase investments in domestic expansion, research and development, and manufacturing capacity, while also reviewing acquisition opportunities in India and international markets such as Europe and Canada.
500488
₹27,520.00
Abbott India
7D
3.0%
1Y
-19.8%